A detailed history of Joel Greenblatt (Gotham Asset Management, LLC) transactions in Biogen Inc. stock. As of the latest transaction made, Gotham Asset Management, LLC holds 42,444 shares of BIIB stock, worth $6.62 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares
42,444
Previous 23,557 80.18%
Holding current value
$6.62 Million
Previous $5.46 Million 50.68%
% of portfolio
0.09%
Previous 0.07%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$189.07 - $236.8 $3.57 Million - $4.47 Million
18,887 Added 80.18%
42,444 $8.23 Million
Q2 2024

Aug 14, 2024

BUY
$190.52 - $236.72 $4.49 Million - $5.58 Million
23,557 New
23,557 $5.46 Million
Q4 2023

Feb 14, 2024

SELL
$222.59 - $267.94 $3.51 Million - $4.22 Million
-15,766 Reduced 81.06%
3,684 $953,000
Q3 2023

Nov 14, 2023

SELL
$253.3 - $285.89 $2.96 Million - $3.34 Million
-11,698 Reduced 37.56%
19,450 $5 Million
Q2 2023

Aug 14, 2023

BUY
$275.25 - $318.06 $3.1 Million - $3.59 Million
11,274 Added 56.73%
31,148 $8.87 Million
Q1 2023

May 15, 2023

BUY
$256.56 - $292.34 $386,122 - $439,971
1,505 Added 8.19%
19,874 $5.53 Million
Q4 2022

Feb 14, 2023

BUY
$252.44 - $306.72 $1.83 Million - $2.22 Million
7,253 Added 65.25%
18,369 $5.09 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $979,485 - $1.35 Million
-5,031 Reduced 31.16%
11,116 $2.97 Million
Q2 2022

Aug 15, 2022

SELL
$187.54 - $223.02 $1.71 Million - $2.03 Million
-9,092 Reduced 36.02%
16,147 $3.29 Million
Q1 2022

May 16, 2022

BUY
$193.77 - $244.14 $2.94 Million - $3.7 Million
15,155 Added 150.29%
25,239 $5.32 Million
Q4 2021

Feb 14, 2022

SELL
$223.92 - $287.77 $819,099 - $1.05 Million
-3,658 Reduced 26.62%
10,084 $2.42 Million
Q3 2021

Nov 15, 2021

BUY
$282.99 - $369.05 $3.07 Million - $4 Million
10,832 Added 372.23%
13,742 $3.89 Million
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $3.09 Million - $4.94 Million
-11,914 Reduced 80.37%
2,910 $1.01 Million
Q1 2021

May 17, 2021

SELL
$242.95 - $284.63 $1.99 Million - $2.33 Million
-8,184 Reduced 35.57%
14,824 $4.15 Million
Q4 2020

Feb 16, 2021

SELL
$236.26 - $355.63 $1.9 Million - $2.86 Million
-8,035 Reduced 25.88%
23,008 $5.63 Million
Q3 2020

Nov 16, 2020

SELL
$264.77 - $305.71 $18.2 Million - $21 Million
-68,839 Reduced 68.92%
31,043 $8.81 Million
Q2 2020

Aug 13, 2020

SELL
$258.66 - $342.55 $8.82 Million - $11.7 Million
-34,093 Reduced 25.45%
99,882 $26.7 Million
Q1 2020

May 15, 2020

SELL
$268.85 - $341.04 $6.93 Million - $8.8 Million
-25,791 Reduced 16.14%
133,975 $42.4 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $3.36 Million - $4.64 Million
-15,261 Reduced 8.72%
159,766 $47.4 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $4.29 Million - $4.81 Million
19,741 Added 12.71%
175,027 $40.8 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $884,615 - $975,098
4,034 Added 2.67%
155,286 $36.3 Million
Q1 2019

May 15, 2019

BUY
$216.71 - $338.96 $9.71 Million - $15.2 Million
44,817 Added 42.11%
151,252 $35.8 Million
Q4 2018

Feb 14, 2019

BUY
$278.5 - $352.75 $7.57 Million - $9.58 Million
27,164 Added 34.27%
106,435 $32 Million
Q3 2018

Nov 14, 2018

SELL
$293.51 - $383.83 $1.71 Million - $2.24 Million
-5,836 Reduced 6.86%
79,271 $28 Million
Q2 2018

Aug 14, 2018

SELL
$257.52 - $306.91 $6.87 Million - $8.19 Million
-26,694 Reduced 23.88%
85,107 $24.7 Million
Q1 2018

May 15, 2018

BUY
$260.13 - $367.91 $6.22 Million - $8.8 Million
23,927 Added 27.23%
111,801 $30.6 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $7.64 Million - $8.56 Million
24,835 Added 39.4%
87,874 $28 Million
Q3 2017

Nov 14, 2017

BUY
$281.15 - $329.69 $17.7 Million - $20.8 Million
63,039
63,039 $19.7 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $22.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track Joel Greenblatt's Portfolio

Track Joel Greenblatt Portfolio

Follow Joel Greenblatt (Gotham Asset Management, LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.